Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 18/20 | 0.44 |
| ▸ | INSR | P06213 | 7/20 | 0.44 |
| ▸ | TXK | P42681 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6416908 | 0.89 | ITK (0.47) | ITKINSRTXKACHE | |
| SCHEMBL6414828 | 0.85 | JAK2 (0.45) | ITKINSRALDH1A1GAAMAPT | |
| SCHEMBL6417112 | 0.85 | PTGER4 (0.44) | ITKINSRALDH1A1GAAMAPT | |
| SCHEMBL6419529 | 0.83 | SMN1; SMN2 (0.47) | ALDH1A1GAAMAPTAGTR1SMN1; SMN2 | |
| SCHEMBL6277030 | 0.82 | RECQL (0.42) | ALDH1A1GAAMAPTAGTR1SMN1; SMN2 | |
| SCHEMBL6416237 | 0.82 | ITK (0.62) | ITKINSRTXK | |
| SCHEMBL6273358 | 0.81 | ACHE (0.43) | ITKINSRALDH1A1GAAMAPT | |
| SCHEMBL6415037 | 0.81 | SMN1; SMN2 (0.39) | ITKINSRALDH1A1GAAMAPT | |
| SCHEMBL6272346 | 0.80 | ACHE (0.39) | ALDH1A1GAAMAPTAGTR1SMN1; SMN2 | |
| SCHEMBL6272962 | 0.80 | HDAC1 (0.43) | ALDH1A1GAAMAPTAGTR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209284-A1 | Tec kinase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209284-A1 | Tec kinase inhibitors | TEC, ITK, TXK | ITK 2/4885INSR 910/4885TXK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.